Hong Kong stock market anomaly | HaploReg (09989.HK) rose more than 10%, with self-developed innovative candidate drug H1710 completing Phase I clinical trial and receiving first dose.

According to the Securities Times APP, Haipu Ray (09989.HK) has risen by more than 10%, as of the time of publication, it has increased by 9.92% to 7.09 Hong Kong dollars, with a transaction amount of 107 million Hong Kong dollars.